Pharmabranche: „Sind nach dieser Nachricht ratlos“: Analysten sehen mögliche Mega-Fusion von Astra Zeneca und BSM skeptisch
In der Pharmabranche könnte sich der potenziell größte Deal der Geschichte anbahnen. Doch was neue Verkaufsschlager hervorbringen soll, wirft an den Märkten viele Fragen auf.
Munich - The pharmaceutical sector was left bewildered on Monday as British drug giant Astra Zeneca reportedly considered a potential mega-fusion with US competitor Bristol Myers Squibb (BMS). The enormous deal, which would be the largest in industry history, sent shockwaves through the markets upon the opening bell. Astra Zeneca's share price dropped by 7.1 percent, while BMS shares rose 2.4 percent prior to the market opening.
However, it remains unclear whether these discussions are ongoing. A spokesman for Astra Zeneca declined to comment, and Bristol Myers Squibb did not respond to inquiries. Analysts are raising significant strategic, financial, and antitrust concerns over the potential mega-fusion. The history of such large-scale mergers shows they often face substantial challenges.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
